Franklin M Berger
CIK 1273885 · Director · last filed 2026-10-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RAIN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
225 FRANKLIN STREET SUITE 2100
BOSTON, MA
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RTSN | Director | 22,517 | — | — | $120.0K | 2 | 2026-10-13 |
| AVIR | Director | 536,097 | $4.41 | $2.36M | -$238.2K | 13 | 2026-06-23 |
| Kezar Life Sciences, Inc. (KZR) Delisted | Director | 0 | $7.29 | $0 | $2.91M | 14 | 2026-05-11 |
| ESSA Pharma Inc. (EPIX) Delisted | Director | 784,404 | $0.20 | $157.8K | $1.36M | 8 | 2024-03-28 |
| RAIN | Director | 0 | $0.54 | $0 | $3.41M | 8 | 2024-01-26 |
| Atreca, Inc. (BCEL) Delisted | Director | 97,808 | $0.15 | $14.7K | $0 | 5 | 2023-06-15 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Director | 0 | $38.00 | $0 | $1.20M | 13 | 2021-04-19 |
| KINETA, INC./DE (PTI) Delisted | Director | 15,308 | — | — | $2.12M | 10 | 2020-07-01 |
| Forte Biosciences, Inc. (TOCA) Delisted | Director | 1,689 | — | — | $0 | 4 | 2019-10-04 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Director | — | $178.75 | — | $0 | 4 | 2019-06-12 |
| Seagen Inc. (SGEN) Delisted | Director | 204,720 | $228.74 | $46.83M | $505.2K | 20 | 2014-02-25 |
| Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Director | 500 | — | — | $1.9K | 2 | 2013-08-22 |
| EMIS | Director | — | $10.38 | — | $0 | 1 | 2009-05-19 |
| Diadexus, Inc. (AXC) Delisted | Director | — | — | — | $0 | 1 | 2008-06-11 |
Recent Filings · Page 4 of 12
120 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-17 | Kezar Life Sciences, Inc. (KZR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-10 | Atreca, Inc. (BCEL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-22 | Kezar Life Sciences, Inc. (KZR) Delisted | Buy (P) | +80,000 | $1.30M | EDGAR |
| 2021-09-23 | Kezar Life Sciences, Inc. (KZR) Delisted | Exer (M) | +26,688 | $170.3K | EDGAR |
| 2021-09-23 | RAIN | Buy (P) | +3,786 | $54.1K | EDGAR |
| 2021-06-30 | Kezar Life Sciences, Inc. (KZR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-21 | AVIR | Grant (A) | — | $0 | EDGAR |
| 2021-06-11 | Atreca, Inc. (BCEL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-18 | RAIN | Grant (A) | — | $0 | EDGAR |
| 2021-04-27 | RAIN | Mixed | +836,540 | $2.12M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.